[go: up one dir, main page]

US20070197637A1 - Use of oligosaccharide for preventing blood clotting in extracorporeal blood circuits - Google Patents

Use of oligosaccharide for preventing blood clotting in extracorporeal blood circuits Download PDF

Info

Publication number
US20070197637A1
US20070197637A1 US11/464,259 US46425906A US2007197637A1 US 20070197637 A1 US20070197637 A1 US 20070197637A1 US 46425906 A US46425906 A US 46425906A US 2007197637 A1 US2007197637 A1 US 2007197637A1
Authority
US
United States
Prior art keywords
sulpho
methyl
glucopyranosyl
tri
extracorporeal blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/464,259
Inventor
Jacobus Stiekema
Jean Herbert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Priority to US11/464,259 priority Critical patent/US20070197637A1/en
Assigned to SANOFI-AVENTIS reassignment SANOFI-AVENTIS ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: STIEKEMA, JACOBUS, HERBERT, JEAN MARC
Publication of US20070197637A1 publication Critical patent/US20070197637A1/en
Assigned to SANOFI reassignment SANOFI CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: SANOFI-AVENTIS
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Definitions

  • the invention relates to the use of a certain oligosaccharide for the manufacture of a medicament for preventing blood clotting in extracorporeal blood circuits. Further the invention relates to a pharmeuceutical composition for said use.
  • Both UFH and LMWH have an effect on several stages of the blood coagulation cascade, both inhibiting factor Xa and thrombin (factor IIa).
  • Factor Xa catalyzes the generation of thrombin and subsequently thrombin regulates the last step in the coagulation cascade.
  • the prime function of thrombin is the cleavage of fibrinogen to generate fibrin monomers, which form an insoluble gel by cross-linking, thereby initiating thrombus formation.
  • UFH and LMWH have thrombolytic properties, i.e. they induce dissolution of the thrombus formed.
  • oligosaccharide results in effective and safe inhibition of blood clotting, e.g. in patients undergoing haemodialysis, without increased bleeding risks.
  • a preferred oligosaccharide for the use according to this invention is the pentasaccharide with the formula methyl O-(2-deoxy-2-sulphoamino-6-O-sulpho- ⁇ -D-glucopyranosyl)-(1 ⁇ 4)-O-( ⁇ -D-glucopyranosyl uronic acid)-(1 ⁇ 4)-O-(2-deoxy-2-sulphoamino-3,6-di-O-sulpho- ⁇ -D-glucopyranosyl)-(1 ⁇ 4)-O-(2-O-sulpho- ⁇ -L-idopyranosyl uronic acid)-(1 ⁇ 4)-2-deoxy-2-sulphoamino-6-O-sulpho- ⁇ -D-glucopyranoside or a pharmaceutically acceptable salt thereof (i.e. salts with counter-ions like hydrogen or, more preferably, alkali or earth-alkali metal ions, like sodium, calcium, or magnesium), having the structure:
  • decasodium salt known by its code name Org 31540 or SR 90107A (described in chemical Synthesis to Glycosaminoglycans, Supplement to Nature 1991, 350, 30-33).
  • extracorporeal blood circuits includes circuits and intravenous infusion lines used for haemodialysis, renal dialysis, haemofiltration, and the like.
  • Preferred extracorporeal cicuits are those used in the treatment of haemodialysis patients.
  • the oligosaccharide can be administered at several stages of the treatment.
  • the oligosaccharide is administered as an intravenous injection to the mammal undergoing treatment.
  • the mammal is a human.
  • Another route of administration of the oligosaccharide is the introduction thereof into a (dialysis) circuit by other means, e.g. by injecting it either gradually or at once into the system upstream of the dialysis membrane simultaneously with the introduction of the blood into the circuit
  • the lines and/or further equipment of the extracorporeal circuit can be furnished with the oligosaccharide, preferably by way of a coating (but not limited to this).
  • the oligosaccharide may be adsorbed in the materials of parts of the equipment, e.g. in the membranes used for dialysis.
  • the oligosaccharide may be administered enterally or parenterally (especially via the subcutaneous or intravenous route) or may be administered via an external source (vide supra), and for humans preferably in a dosage of 0,001-10 mg per kg body weight per dialysis. More preferably, the pentasaccharide is administered at doses of between 0.30 mg and 30 mg per patient per dialysis.
  • the oligosaccharide may be used alone or may be presented as a pharmaceutical composition. Accordingly, the present invention further provides a pharmaceutical composition for preventing blood clotting in an extracorporeal blood circuit comprising said oligosaccharide together with pharmaceutically acceptable auxiliaries and optionally other therapeutic agents.
  • pharmaceutically acceptable means being compatible with the other ingredients of the composition and not deleterious to the recipients thereof.
  • compositions include e.g. those suitable for oral, sublingual, subcutaneous, intravenous, intramuscular, transdermal, transmucosal, local, or rectal administration, and the like, all in unit dosage forms for administration.
  • the active ingredient may be presented as discrete units, such as tablets, capsules, powders, granulates, solutions, suspensions, and the like.
  • the pharmaceutical composition of the invention may be presented in unit-dose or multi-dose containers, e.g. injection liquids in predetermined amounts, for example in sealed vials and ampoules, and may also be stored in a freeze dried (lyophilzed) condition requiring only the addition of sterile liquid carrier, e.g. water, prior to use.
  • the oligosaccharide may be compressed into solid dosage units, such as pills, tablets, or be processed into capsules or suppositories.
  • the oligosaccharide can be applied as a fluid composition, e.g. as an injection preparation, in the form of a solution, suspension, emulsion, or as a spray, e.g. a nasal spray.
  • oligosaccharide for use as a coating according to the invention, for example pharmaceutically acceptable polymers may be used as a matrix for the oligosaccharide. Also coatings are included, in which the oligosaccharide is chemically (e.g. covalently) linked to the surface without loss of its activity. Any parmaceutically acceptable coating may be suitable for this purpose, prepared according to methods conventional in the art.
  • Suitable carriers with which the oligosaccharides of the invention can be administered as solid compositions include lactose, starch, cellulose derivatives and the like, or mixtures thereof, used in suitable amounts.
  • aqueous suspensions, isotone saline solutions and sterile injectable solutions may be used, containing pharmaceutically acceptable dispersing agents and/or wetting agents, such as propylene glycol or butylene glycol.
  • compositions according to the invention may also be presented in the form of a veterinary composition, such compositions may be prepared by methods conventional in the art.
  • the invention further includes a pharmaceutical composition, as hereinbefore described, in combination with packaging material suitable for said composition, said packaging material including instructions for the use of the composition for the use as hereinbefore described.
  • the pentasaccharide Org 31540/SR 90107 A as a representative compound for use according to the present invention, has been subject to a pilot clinical study in 12 patients undergoing chronic intermittent haemodialysis.
  • block A 10 mg of Org 31540/SR 90107 A was administered.
  • block B 8, 6, and 4 mg of Org 31540/SR 90107 A were used.
  • Medication was given as an intravenous bolus predialysis for 1 dialysis each week. Efficacy was assessed by determining patency of the dialyzer, buffer and bubble chamber, every hour during dialysis by visual examination and by blood sampling of specific coagualtion, heamatologic and biochemical parameters. Anti-Xa plasma samples, to determine pharmacokinetics, were taken every hour during dialysis and 1 hour after dialysis and daily for 3 days post-dialysis. Safety was assessed by evaluating major and minor bleeding complications each dialysis.
  • the pentasaccharide Org 31540/SR 90107 A is a safe (no increased haemorrhagic risks) and effective (at several doses) anticoagulant to prevent clotting in the extracorporeal blood circuit in haemodialysis patients.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • External Artificial Organs (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)

Abstract

A method for preventing clotting in an extracorporeal blood circuit by administering a synthetic oligosaccharide that is a selective inhibitor of factor Xa, acting via antithrobmin III.

Description

  • The invention relates to the use of a certain oligosaccharide for the manufacture of a medicament for preventing blood clotting in extracorporeal blood circuits. Further the invention relates to a pharmeuceutical composition for said use.
  • Blood clotting in extracorporeal blood circuits needs to be prevented. Otherwise, blood coagulation occurs as soon as blood contacts artificial surfaces. As a remedy, usually unfractionated heparin (UFH) or low molecular weight heparins (LMWH) are used as anticoagulants.
  • Both UFH and LMWH have an effect on several stages of the blood coagulation cascade, both inhibiting factor Xa and thrombin (factor IIa). Factor Xa catalyzes the generation of thrombin and subsequently thrombin regulates the last step in the coagulation cascade. The prime function of thrombin is the cleavage of fibrinogen to generate fibrin monomers, which form an insoluble gel by cross-linking, thereby initiating thrombus formation. UFH and LMWH have thrombolytic properties, i.e. they induce dissolution of the thrombus formed.
  • Contrary to UFH and LMWH, some synthetic oligosaccharides, especially oligosaccharides described in EP 84,899 and U.S. Pat. No. 5,378,829, highly selectively inhibit factor Xa via antithrombin III (ATIII) but do not have any activity on thrombin. However, notwithstanding the absence of any capacity to inhibit thrombin or to promote thrombolysis, it appeared that those oligosaccharides inhibit thrombous formation, e.g. as occurring in extracorporeal blood circuits. Thus, surprisingly, it has now been found that a synthetic oligosaccharide which is a selective inhibitor of factor Xa, acting via antithrobmin III, is useful for preventing blood clotting in patients with an extracorporeal blood circuit.
  • The use of the oligosaccharide according to this invention results in effective and safe inhibition of blood clotting, e.g. in patients undergoing haemodialysis, without increased bleeding risks.
  • A preferred oligosaccharide for the use according to this invention is the pentasaccharide with the formula methyl O-(2-deoxy-2-sulphoamino-6-O-sulpho-α-D-glucopyranosyl)-(1 →4)-O-(β-D-glucopyranosyl uronic acid)-(1→4)-O-(2-deoxy-2-sulphoamino-3,6-di-O-sulpho-α-D-glucopyranosyl)-(1→4)-O-(2-O-sulpho-α-L-idopyranosyl uronic acid)-(1→4)-2-deoxy-2-sulphoamino-6-O-sulpho-α-D-glucopyranoside or a pharmaceutically acceptable salt thereof (i.e. salts with counter-ions like hydrogen or, more preferably, alkali or earth-alkali metal ions, like sodium, calcium, or magnesium), having the structure:
    Figure US20070197637A1-20070823-C00001
  • Particularly preferred is its decasodium salt, known by its code name Org 31540 or SR 90107A (described in chemical Synthesis to Glycosaminoglycans, Supplement to Nature 1991, 350, 30-33).
  • Other advantageous pentasaccharides are: methyl O-(3,4-di-O-methyl-2,6-di-O-sulpho-α-D-glucopyranosyl)-(1→4)-O-(3-O-methyl-2-O-sulpho-β-D-glucopyranosyl uronic acid)-(1→4)-O-(2,3,6-tri-O-sulpho-α-D-glucopyranosyl)-(1→4)-O-(3-methyl-2-O-sulpho-α-L-idopyranosyl uronic acid)-(1→4)-2,3,6-tri-O-sulpho-α-D-glucopyranoside or a pharmaceutically acceptable salt thereof (especially its dodecasodium salt described in U.S. Pat. No. 5,378,829), having the structure
    Figure US20070197637A1-20070823-C00002
    and methyl O-(2,3,4-tri-O-methyl-6-O-sulpho-α-D-glucopyranosyl)-(1→4)-O-(2,3-di-O-methyl-β-D-glucopyranosyl uronic acid)-(1→4)-O-(2,3,6-tri-O-sulpho-α-D-glucopyranosyl)-(1→4)-O-(2,3-di-O-methyl-α-L-idopyranosyl uronic acid)-(1→4)-2,3,6-tri-O-sulpho-α-D-glucopyranoside or a pharmaceutically acceptable salt thereof (especially its nonasodium salt also described in U.S. Pat. No. 5,378,829), having the structure
    Figure US20070197637A1-20070823-C00003
  • The use in patients with extracorporeal blood circuits according to the invention includes circuits and intravenous infusion lines used for haemodialysis, renal dialysis, haemofiltration, and the like. Preferred extracorporeal cicuits are those used in the treatment of haemodialysis patients.
  • The oligosaccharide can be administered at several stages of the treatment. Preferably, but not limited to this route of administration, the oligosaccharide is administered as an intravenous injection to the mammal undergoing treatment. Preferably, the mammal is a human.
  • Another route of administration of the oligosaccharide is the introduction thereof into a (dialysis) circuit by other means, e.g. by injecting it either gradually or at once into the system upstream of the dialysis membrane simultaneously with the introduction of the blood into the circuit Moreover, the lines and/or further equipment of the extracorporeal circuit can be furnished with the oligosaccharide, preferably by way of a coating (but not limited to this). Alternatively, the oligosaccharide may be adsorbed in the materials of parts of the equipment, e.g. in the membranes used for dialysis.
  • For use according to the invention, the oligosaccharide may be administered enterally or parenterally (especially via the subcutaneous or intravenous route) or may be administered via an external source (vide supra), and for humans preferably in a dosage of 0,001-10 mg per kg body weight per dialysis. More preferably, the pentasaccharide is administered at doses of between 0.30 mg and 30 mg per patient per dialysis.
  • The oligosaccharide may be used alone or may be presented as a pharmaceutical composition. Accordingly, the present invention further provides a pharmaceutical composition for preventing blood clotting in an extracorporeal blood circuit comprising said oligosaccharide together with pharmaceutically acceptable auxiliaries and optionally other therapeutic agents. The term “acceptable” means being compatible with the other ingredients of the composition and not deleterious to the recipients thereof.
  • Compositions include e.g. those suitable for oral, sublingual, subcutaneous, intravenous, intramuscular, transdermal, transmucosal, local, or rectal administration, and the like, all in unit dosage forms for administration.
  • For oral administration, the active ingredient may be presented as discrete units, such as tablets, capsules, powders, granulates, solutions, suspensions, and the like. For parenteral administration, the pharmaceutical composition of the invention may be presented in unit-dose or multi-dose containers, e.g. injection liquids in predetermined amounts, for example in sealed vials and ampoules, and may also be stored in a freeze dried (lyophilzed) condition requiring only the addition of sterile liquid carrier, e.g. water, prior to use.
  • Mixed with such pharmaceutically acceptable auxiliaries, e.g. as described in the standard reference, Gennaro et al., Remington's Pharmaceutical Sciences, (18th ed., Mack Publishing Company, 1990, see especially Part 8: Pharmaceutical Preparations and Their Manufacture), the oligosaccharide may be compressed into solid dosage units, such as pills, tablets, or be processed into capsules or suppositories. By means of pharmaceutically acceptable liquids the oligosaccharide can be applied as a fluid composition, e.g. as an injection preparation, in the form of a solution, suspension, emulsion, or as a spray, e.g. a nasal spray.
  • For use as a coating according to the invention, for example pharmaceutically acceptable polymers may be used as a matrix for the oligosaccharide. Also coatings are included, in which the oligosaccharide is chemically (e.g. covalently) linked to the surface without loss of its activity. Any parmaceutically acceptable coating may be suitable for this purpose, prepared according to methods conventional in the art.
  • For making solid dosage units, the use of conventional additives such as fillers, colorants, polymeric binders and the like is contemplated. In general any pharmaceutically acceptable additive which does not interfere with the function of the active compounds can be used. Suitable carriers with which the oligosaccharides of the invention can be administered as solid compositions include lactose, starch, cellulose derivatives and the like, or mixtures thereof, used in suitable amounts. For parenteral administration, aqueous suspensions, isotone saline solutions and sterile injectable solutions may be used, containing pharmaceutically acceptable dispersing agents and/or wetting agents, such as propylene glycol or butylene glycol.
  • The pharmaceutical composition according to the invention may also be presented in the form of a veterinary composition, such compositions may be prepared by methods conventional in the art.
  • The invention further includes a pharmaceutical composition, as hereinbefore described, in combination with packaging material suitable for said composition, said packaging material including instructions for the use of the composition for the use as hereinbefore described.
  • The invention is further illustrated by the following example. This should not be considered to be limiting in any way.
    • EXAMPLE
  • The pentasaccharide Org 31540/SR 90107 A, as a representative compound for use according to the present invention, has been subject to a pilot clinical study in 12 patients undergoing chronic intermittent haemodialysis.
  • The study consisted of 2 phases (block A and block B). In block A, 10 mg of Org 31540/SR 90107 A was administered. Thereafter, in block B, 8, 6, and 4 mg of Org 31540/SR 90107 A were used.
  • Medication was given as an intravenous bolus predialysis for 1 dialysis each week. Efficacy was assessed by determining patency of the dialyzer, buffer and bubble chamber, every hour during dialysis by visual examination and by blood sampling of specific coagualtion, heamatologic and biochemical parameters. Anti-Xa plasma samples, to determine pharmacokinetics, were taken every hour during dialysis and 1 hour after dialysis and daily for 3 days post-dialysis. Safety was assessed by evaluating major and minor bleeding complications each dialysis.
  • Results: All patients have completed the study. Dialysis could be performed without total clotting of the extracorporeal circuit in all patients for all study dialyses. Only in one patient a clot in the buffer chamber made dialysis impossible half an hour before the end of the last dialysis. No minor or major bleedings were recorded.
  • Conclusion: The pentasaccharide Org 31540/SR 90107 A is a safe (no increased haemorrhagic risks) and effective (at several doses) anticoagulant to prevent clotting in the extracorporeal blood circuit in haemodialysis patients.

Claims (16)

1. A method for preventing clotting in an extracorporeal blood circuit, induced by contact with surfaces, for a patient undergoing chronic, intermittent, extracorporeal blood treatment, comprising:
administering to the patient for each treatment an amount of from 0.001 to 10 mg of methyl O-(3,4-di-O-methyl-2,6-di-O-sulpho-α-D-glucopyranosyl-(1→4)-O-(3-O-methyl-2-O-sulpho-β-D-glucopyranosyl uronic acid)-(1→4)-O-(2,36-tri-O-sulpho-α-D-glucopyranosyl)-(1→4)-O-(3-O-methyl-2-O-sulpho-α-L-idopyranosyl uronic acid)-(1→4)-(2,3,6-tri-O-sulpho-α-D-glucopyranoside, or a salt thereof, per kg body weight of the patient.
2. A method for preventing clotting in an extracorporeal blood circuit, induced by contact with surfaces, for a patient undergoing chronic, intermittent, extracorporeal blood treatment, comprising:
administering to the patient for each treatment an amount of from 0.30 to 30 mg of methyl O-(3,4-di-O-methyl-2,6-di-O-sulpho-α-D-glucopyranosyl-(1→4)-O-(3-O-methyl-2-O-sulpho-β-D-glucopyranosyl uronic acid)-(1→4)-O--2,3,6-tri-O-sulpho-α-D-glucopyranosyl)-(1→4)-O-(3-O-methyl-2-O-sulpho-α-L-idopyranosyl uronic acid)-(1→4)-2,3,6-tri-O-sulpho-α-D-glucopyranoside, or salt thereof.
3. The method of claim 1, comprising administering a dodecasodium salt thereof.
4. The method of claim 2, comprising administering a dodecasodium salt thereof.
5. A method for preventing clotting in an extracorporeal blood circuit, induced by contact with surfaces, for a patient undergoing chronic, intermittent, extracorporeal blood treatment, comprising:
administering to the patient for each treatment an amount of from 0.001 to 10 mg of methyl O-(2,3,4-tri-O-methyl-6-O-sulpho-α-D-glucopyranosyl)-(1→4)-O-(2,3-di-O-methyl-β-D-glucopyranosyl uronic acid)-(1→4)-O-(2,3,6-tri-O-sulpho-α-D-glucopyranosyl)-(1→4)-O-(2,3-di-O-methyl-α-L-idopyranosyl uronic acid)-(1→4)-2,3,6,-tri-O-sulpho-α-D-glucopyranoside, or a salt thereof, per kg body weight of the patient.
6. A method for preventing clotting in an extracorporeal blood circuit, induced by contact with surfaces, for a patient undergoing chronic, intermittent, extracorporeal blood treatment, comprising:
administering to the patient for each treatment an amount of from 0.30 to 30 mg of methyl O-(2,3,4-tri-O-methyl-6-O-sulpho-α-D-glucopyranosyl)-(1→4)-O-(2,3-di-O-methyl-β-D-glucopyranosyl uronic acid)-(1→4)-O-(2,3,6-tri-O-sulpho-α-D-glucopyranosyl)-(1→4)-O-(2,3-di-O-methyl-α-L-idopyranosyl uronic acid)-(1→4)-2,3,6,-tri-O-sulpho-α-D-glucopyranoside, or a salt thereof.
7. The method of claim 5, comprising administering a nonasodium salt thereof.
8. The method of claim 6, comprising administering a nonasodium salt thereof.
9. A method for preventing clotting in an extracorporeal blood circuit, induced by contact with surfaces, for a patient undergoing chronic, intermittent, extracorporeal blood treatment, comprising:
administering to the circuit for each treatment an amount form 0.001 to 10 mg of methyl O-(3,4-di-O-methyl-2,6-di-O-sulpho-α-D-glucopyranosyl-(1→4)-O-(3-O-methyl-2-O-sulpho-β-D-glucopyranosyl uronic acid)-(1→4)-O-(2,3,6-tri-O-sulpho-α-D-glucopyranosyl)-(1→4)-O-(3-O-methyl-2-O-sulpho-α-L-idipyranosyl uronic acid)-(1→4)-2,3,6-tri-O-sulpho-α-D-glucopyranoside, or salt thereof, per kg body weight of the patient.
10. A method for preventing clotting in an extracorporeal blood circuit, induced by contact with surfaces, for a patient undergoing chronic, intermittent, extracorporeal blood treatment, comprising:
administering to the circuit for each treatment an amount of from 0.30 to 30 mg of methyl O-(3,4-di-O-methyl-2,6-di-O-sulpho-α-D-glucopyranosyl-(1→4)-O-(3-O-methyl-2-O-sulpho-β-D-glucopyranosyl uronic acid)-(1→4)-O-(2,3,6-tri-O-sulpho-α-D-glucopyranosyl)-(→4)-O-(3-O-methyl-2-O-sulpho-α-L-idopyranosyl uronic acid)-(1→4)-(2,3,6-tri-O-sulpho-α-D-glucopyranoside or a salt thereof.
11. The method of claim 9, comprising administering a dodecasodium salt thereof.
12. The method of claim 10, comprising administering a dodecasodium salt thereof.
13. A method for preventing clotting in an extracorporeal blood circuit, induced by contact with surfaces, for a patient undergoing chronic, intermittent, extracorporeal blood treatment, comprising:
administering to the circuit for each treatment an amount of from 0.001 to 10 mg of methyl O-(2,3,4-tri-O-methyl-6-O-sulpho-α-D-glucopyranosyl)-(1→4)-O-(2,3-di-O-methyl-β-D-glucopyranosyl uronic acid)-(1→4)-O-(2,3,6-tri-O-sulpho-α-D-glucopyranosyl)-(1→4)-O-(2,3-di-O-methyl-α-L-idopyranosyl uronic acid)-(1→4)-2,3,6-tri-O-sulpho-α-D-glucopyranoside or a salt thereof per kg body weight of the patient.
14. A method for preventing clotting induced by contact with surfaces in an extracorporeal blood circuit for a patient undergoing chronic, intermittent, extracorporeal blood treatment comprising:
administering to the circuit for each treatment an amount of from 0.30 to 30 mg of methyl O-(2,3,4-tri-O-methyl-6-O-sulpho-α-D-glucopyranosyl)-(1→4)-O-(2,3-di-O-methyl-β-D-glucopyranosyl uronic acid)-(1→4)-O-(2,3,6-tri-O-sulpho-α-D-glucopyranosyl)-(1→4)-O-(2,3-di-O-methyl-α-L-idopyranosyl uronic acid)-(1→4)-2,3,6,-tri-O-sulpho-α-D-glucopyranoside or a salt thereof.
15. The method of claim 13, comprising administering a nonasodium salt thereof.
16. The method of claim 14, comprising administering a nonasodium salt thereof.
US11/464,259 1997-05-27 2006-08-14 Use of oligosaccharide for preventing blood clotting in extracorporeal blood circuits Abandoned US20070197637A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/464,259 US20070197637A1 (en) 1997-05-27 2006-08-14 Use of oligosaccharide for preventing blood clotting in extracorporeal blood circuits

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP97201586.1 1997-05-27
EP97201586 1997-05-27
PCT/EP1998/003174 WO1998053829A1 (en) 1997-05-27 1998-05-22 Use of oligosaccharide for preventing blood clotting in extracorporeal blood circuits
US09/424,626 US6391339B1 (en) 1997-05-27 1998-05-22 Use of oligosaccharide for preventing blood clotting in extracorporeal blood circuits
US10/005,793 US20020040012A1 (en) 1997-05-27 2001-11-02 Use of oligosaccharide for preventing blood clotting in extracorporeal blood circuits
US11/464,259 US20070197637A1 (en) 1997-05-27 2006-08-14 Use of oligosaccharide for preventing blood clotting in extracorporeal blood circuits

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/005,793 Continuation US20020040012A1 (en) 1997-05-27 2001-11-02 Use of oligosaccharide for preventing blood clotting in extracorporeal blood circuits

Publications (1)

Publication Number Publication Date
US20070197637A1 true US20070197637A1 (en) 2007-08-23

Family

ID=8228366

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/424,626 Expired - Lifetime US6391339B1 (en) 1997-05-27 1998-05-22 Use of oligosaccharide for preventing blood clotting in extracorporeal blood circuits
US10/005,793 Abandoned US20020040012A1 (en) 1997-05-27 2001-11-02 Use of oligosaccharide for preventing blood clotting in extracorporeal blood circuits
US11/464,259 Abandoned US20070197637A1 (en) 1997-05-27 2006-08-14 Use of oligosaccharide for preventing blood clotting in extracorporeal blood circuits

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US09/424,626 Expired - Lifetime US6391339B1 (en) 1997-05-27 1998-05-22 Use of oligosaccharide for preventing blood clotting in extracorporeal blood circuits
US10/005,793 Abandoned US20020040012A1 (en) 1997-05-27 2001-11-02 Use of oligosaccharide for preventing blood clotting in extracorporeal blood circuits

Country Status (12)

Country Link
US (3) US6391339B1 (en)
EP (2) EP0984785B1 (en)
JP (2) JP2002503270A (en)
AT (1) ATE307596T1 (en)
AU (1) AU8211398A (en)
BR (1) BR9809478A (en)
CA (1) CA2289522A1 (en)
DE (1) DE69832066T2 (en)
DK (1) DK0984785T3 (en)
ES (1) ES2251090T3 (en)
NO (1) NO325142B1 (en)
WO (1) WO1998053829A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391339B1 (en) * 1997-05-27 2002-05-21 Akzo Nobel N.V. Use of oligosaccharide for preventing blood clotting in extracorporeal blood circuits
FR2804328B1 (en) 2000-01-27 2002-03-15 Hospal Ind NON-THROMBOGENIC SEMI-PERMEABLE MEMBRANE AND MANUFACTURING METHOD
JP2006096668A (en) * 2002-11-08 2006-04-13 Ono Pharmaceut Co Ltd A pharmaceutical comprising a combination of an elastase inhibitor and a blood coagulation system and / or fibrinolytic enzyme inhibitor
CA2782311C (en) * 2009-12-01 2017-06-27 Robert S. Ward Method for removing cytokines from blood with surface immobilized polysaccharides
WO2013188073A1 (en) 2012-06-13 2013-12-19 Exthera Medical, Llc Use of heparin and carbohydrates to treat cancer
MX382486B (en) 2013-11-08 2025-03-13 Exthera Medical Corp METHODS FOR DIAGNOSTICS OF INFECTIOUS DISEASES USING ADSORPTION MEDIUM.
WO2015164198A1 (en) 2014-04-24 2015-10-29 Exthera Medical Corporation Method for removing bacteria from blood using high flow rate
US11911551B2 (en) 2016-03-02 2024-02-27 Exthera Medical Corporation Method for treating drug intoxication
WO2020231830A1 (en) 2019-05-16 2020-11-19 Exthera Medical Corporation Method for modulating endothelial glycocalyx structure

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2002A (en) * 1841-03-12 Tor and planter for plowing
US4331687A (en) * 1980-03-08 1982-05-25 Rohm Pharma Gmbh Treatment of Parkinson's disease
US4331697A (en) * 1980-09-02 1982-05-25 Teijin Limited Novel heparin derivative, method for production thereof, and method for rendering biomedical materials antithrombotic by use of the novel heparin derivative
US4801583A (en) * 1982-01-15 1989-01-31 Choay S.A. Oligosaccharides and their biological applications
US4818816A (en) * 1981-04-28 1989-04-04 Choay, S.A. Process for the organic synthesis of oligosaccharides and derivatives thereof
US4987223A (en) * 1981-12-23 1991-01-22 Choay S.A. Derivatives of the uronic acid
US5252213A (en) * 1989-06-20 1993-10-12 University Of Washington Dry dialysate composition
US5256559A (en) * 1988-03-04 1993-10-26 Biogen, Inc. Methods and compositions for inhibiting platelet aggregation
US5378829A (en) * 1990-04-23 1995-01-03 Akzo N.V. Sulfated glycosaminoglycanoid derivatives of the heparin and heparan sulfate type
US5417969A (en) * 1991-09-20 1995-05-23 Baxter International Inc. Process for reducing the thrombogenicity of biomaterials
US5872110A (en) * 1996-05-08 1999-02-16 Akzo Nobel N.V. And Sanofi Heparin-like derivatives
US6339074B1 (en) * 1994-03-23 2002-01-15 Fidia Advanced Biopolymers, Srl Sulfated hyaluronic acid and esters thereof
US20020040012A1 (en) * 1997-05-27 2002-04-04 Johannes Stiekema Jacobus Christianus Use of oligosaccharide for preventing blood clotting in extracorporeal blood circuits
US6391369B1 (en) * 1996-03-27 2002-05-21 Bunge Foods Corporation Selectively hydrogenated high oleic oil compositions and process

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU563351C (en) * 1982-01-15 2003-06-19 Glaxo Group Limited Synthesis of oligosaccharides
JPS63218691A (en) * 1987-03-09 1988-09-12 Rikagaku Kenkyusho Novel pentasaccharide compound and its production method, and anticoagulant and antithrombotic agent
EP0300099A1 (en) * 1987-07-20 1989-01-25 Akzo N.V. New pentasaccharides

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2002A (en) * 1841-03-12 Tor and planter for plowing
US4331687A (en) * 1980-03-08 1982-05-25 Rohm Pharma Gmbh Treatment of Parkinson's disease
US4331697A (en) * 1980-09-02 1982-05-25 Teijin Limited Novel heparin derivative, method for production thereof, and method for rendering biomedical materials antithrombotic by use of the novel heparin derivative
US4818816A (en) * 1981-04-28 1989-04-04 Choay, S.A. Process for the organic synthesis of oligosaccharides and derivatives thereof
US4987223A (en) * 1981-12-23 1991-01-22 Choay S.A. Derivatives of the uronic acid
US4801583A (en) * 1982-01-15 1989-01-31 Choay S.A. Oligosaccharides and their biological applications
US5256559A (en) * 1988-03-04 1993-10-26 Biogen, Inc. Methods and compositions for inhibiting platelet aggregation
US5252213A (en) * 1989-06-20 1993-10-12 University Of Washington Dry dialysate composition
US5378829A (en) * 1990-04-23 1995-01-03 Akzo N.V. Sulfated glycosaminoglycanoid derivatives of the heparin and heparan sulfate type
US5417969A (en) * 1991-09-20 1995-05-23 Baxter International Inc. Process for reducing the thrombogenicity of biomaterials
US6339074B1 (en) * 1994-03-23 2002-01-15 Fidia Advanced Biopolymers, Srl Sulfated hyaluronic acid and esters thereof
US6391369B1 (en) * 1996-03-27 2002-05-21 Bunge Foods Corporation Selectively hydrogenated high oleic oil compositions and process
US5872110A (en) * 1996-05-08 1999-02-16 Akzo Nobel N.V. And Sanofi Heparin-like derivatives
US20020040012A1 (en) * 1997-05-27 2002-04-04 Johannes Stiekema Jacobus Christianus Use of oligosaccharide for preventing blood clotting in extracorporeal blood circuits
US6391339B1 (en) * 1997-05-27 2002-05-21 Akzo Nobel N.V. Use of oligosaccharide for preventing blood clotting in extracorporeal blood circuits

Also Published As

Publication number Publication date
EP0984785A1 (en) 2000-03-15
US20020040012A1 (en) 2002-04-04
ATE307596T1 (en) 2005-11-15
US6391339B1 (en) 2002-05-21
ES2251090T3 (en) 2006-04-16
EP1593380A3 (en) 2008-06-11
AU8211398A (en) 1998-12-30
BR9809478A (en) 2000-06-20
CA2289522A1 (en) 1998-12-03
EP1593380A2 (en) 2005-11-09
WO1998053829A1 (en) 1998-12-03
NO995800D0 (en) 1999-11-26
JP2010013455A (en) 2010-01-21
DE69832066D1 (en) 2005-12-01
JP2002503270A (en) 2002-01-29
EP0984785B1 (en) 2005-10-26
NO995800L (en) 1999-11-26
DE69832066T2 (en) 2006-07-13
NO325142B1 (en) 2008-02-11
DK0984785T3 (en) 2006-01-30

Similar Documents

Publication Publication Date Title
JP2010013455A (en) Use of oligosaccharide for preventing blood clotting in extracorporeal blood circuits
RU2153506C2 (en) Dermatan sulfate or its salt, antithrombotic agents, method of prophylaxis and treatment of thrombosis, method of prophylaxis or treatment of disseminated intravascular coagulation syndrome, method of myocardium infarction treatment
Ryan et al. Antithrombotic properties of dermatan sulphate (MF 701) in haemodialysis for chronic renal failure
Ryan et al. Dose finding study of a low molecular weight heparin, Innohep, in haemodialysis
Nenci Dermatan sulphate as an antithrombotic drug
Simpson et al. Long-term use of the low molecular weight heparin tinzaparin in haemodialysis
JP2000300661A (en) Anticoagulant / sterilizer compositions and methods
Anastassiades et al. A low-molecular-weight heparin (Kabi 2165,‘Fragmin’) in repeated use for haemodialysis: Prevention of clotting and prolongation of the venous compression time in comparison with commercial unfractionated heparin
Moriniere et al. Low-molecular-weight heparin Fraxiparin® in chronic hemodialysis: a dose-finding study
MXPA99010965A (en) Use of oligosaccharide for preventing blood clotting in extracorporeal blood circuits
Ireland et al. Low molecular weight heparin in haemodialysis for chronic renal failure: dose finding study of CY222
US20040038932A1 (en) Antithrombotic compositions
EP1471924B1 (en) Idraparinux (sanorg 34006) for treatment and secondary prophylaxis of venous thromboemolic events in patients with deep venous thrombosis
Oguma et al. Clinical effect of low molecular weight heparin (fragmin) on DIC: a multicenter cooperative study in Japan
EP0515550B1 (en) Heparin neutralization with platelet factor 4
Bauer et al. Anticoagulant properties of three mucopolysaccharides used in rheumatology
Carter New developments in acute anticoagulation therapy: What improvements over traditional heparin are on the horizon?
Berry et al. Activity of a sub-cutaneously administered novel mixed micellar formulation of argatroban in rat and rabbit models of venous thrombosis
AU2003205664A1 (en) Idraparinux(sanorg 34006)for treatment and secondary prophylaxis of venous thromboemolic events in patients with deep venous thrombosis
AU726883B2 (en) Use of sulfated oligosaccharides as inhibitors of cardiovascular disease
Bergqvist Low-dose heparin
Tosukowong et al. Pharmacokinetics of Intravenous Fraxiparine in Thai Healthy Controls and Thai Chronic
JPH10251153A (en) Compositions containing a combination of aspirin and anti-Xa oligosaccharide and use of anti-Xa oligosaccharide optionally in combination with aspirin
CA2369096A1 (en) Use of increased-molecular-weight hirudin as an anticoagulant in extracorporeal kidney replacement therapy
EP1321152A1 (en) Antidote for org 31540/SR 90107A

Legal Events

Date Code Title Description
AS Assignment

Owner name: SANOFI-AVENTIS, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:STIEKEMA, JACOBUS;HERBERT, JEAN MARC;REEL/FRAME:019153/0097;SIGNING DATES FROM 20061112 TO 20070402

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: SANOFI, FRANCE

Free format text: CHANGE OF NAME;ASSIGNOR:SANOFI-AVENTIS;REEL/FRAME:028413/0927

Effective date: 20110511